Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and other product candidates in various stages of clinical and preclinical development. It has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in New York, New York.
IPO Year: 2012
Exchange: NASDAQ
Website: interceptpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/13/2023 | $8.00 → $19.00 | Sell → Buy | H.C. Wainwright |
| 6/29/2023 | $12.00 → $18.00 | Hold → Buy | Canaccord Genuity |
| 5/23/2023 | Buy → Hold | Needham | |
| 5/22/2023 | $8.00 | Neutral → Sell | H.C. Wainwright |
| 5/17/2023 | Outperform → Mkt Perform | Raymond James | |
| 3/8/2022 | $31.00 → $29.00 | Hold | Canaccord Genuity |
| 3/3/2022 | $22.00 → $16.00 | Sector Perform | RBC Capital |
| 3/3/2022 | $30.00 → $25.00 | Buy | Needham |
| 3/3/2022 | $30.00 → $27.00 | Market Perform | SVB Leerink |
| 1/11/2022 | $25.00 → $30.00 | Neutral → Buy | B. Riley Securities |